Zhou Rong sold $239K of AMPH

Amphastar Pharmaceuticals reported Q3 gross margin decline to 48% from 51% YoY, citing lower pricing for BAQSIMI and increased manufacturing costs. The company expects higher remediation expenses in coming quarters. Amphastar aims to reduce a $12.5M backlog and sees continued lidocaine demand. It remains on track for potential 2027 launches of insulin aspart biosimilar and AMP-018, with other pipeline updates. Operating cash flow was $43.3M, and the board authorized $50M for share repurchases.

Amphastar Pharmaceuticals (AMPH) reported Q3 2026 revenue of $207.6M, up 8.2% YoY and 5.9% above estimates. Adjusted EPS of $1.14 beat estimates by 32.8%. Operating margin was 24.5%, in line with the prior year. The company cited strong sales of key products and pipeline advancements. Shares rose 7.2% post-results.

Amphastar Pharmaceuticals reported Q3 2026 revenue of $207.61M, up 8.2% YoY, and net income of $37.76M, up 117.7% YoY. Growth in BAQSIMI, Primatene MIST, and lidocaine sales offset declines in epinephrine and glucagon. New ipratropium bromide sales contributed $6.6M. Lower expenses also boosted income.

Amphastar reported Q3 2026 revenue of $207.6M, up 8% YoY, with GAAP net income of $37.8M. Adjusted EPS was $1.14. Key products like BAQSIMI and Primatene MIST saw sales growth, while Lidocaine and Ipratropium bromide performed strongly. Teriparatide and API sales also contributed to growth. Manufacturing issues impacted some product sales and expenses.

Amphastar Pharmaceuticals, Inc. (AMPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 ​ Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2026 ​ - Net revenues of $207.6 million for the three months ended September 30, 2026 ​ - GAAP net income of $37.8 million, or $0.87 per share, for the third quarter ​ - Ad

Amphastar Pharmaceuticals reported Q3 2026 net revenues of $207.6M, up 8% YoY. GAAP net income was $37.8M ($0.87 per share), while adjusted non-GAAP net income was $49.3M ($1.14 per share). Growth was driven by BAQSIMI® and Primatene MIST® sales. The company also announced a $50M increase to its share buyback program.